Estland - Estnisch - Ravimiamet

astrazeneca ab - budesoniid - nebuliseeritav suspensioon - 0,25mg 1ml 2ml 20tk

Estland - Estnisch - Ravimiamet

astrazeneca ab - budesoniid - inhalatsioonipulber - 0,1mg 1annus 200annus 1tk

Estland - Estnisch - Ravimiamet

astrazeneca uk limited - budesoniid - toimeainet prolongeeritult vabastav kõvakapsel - 3mg 100tk

Estland - Estnisch - Ravimiamet

astrazeneca uk limited - budesoniid - rektaalsuspensiooni tablett ja lahusti - 2mg 7tk

Europäische Union - Estnisch - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Estland - Estnisch - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsioonipulber - 4,5mcg+80mcg 1annus 120annus 3tk; 4,5mcg+80mcg 1annus 60annus 1tk; 4,5mcg+80mcg 1annus 120annus 1tk; 4,5mcg+80mcg 1annus 60annus 18tk; 4,5mcg+80mcg 1annus 60annus 2tk; 4,5mcg+80mcg 1annus 60annus 10tk; 4,5mcg+80mcg 1annus 120annus 10tk; 4,5mcg+80mcg 1annus 120annus 18tk; 4,5mcg+80mcg 1annus 60annus 3tk

Estland - Estnisch - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsioonipulber - 4,5mcg+160mcg 1annus 120annus 10tk; 4,5mcg+160mcg 1annus 60annus 1tk; 4,5mcg+160mcg 1annus 120annus 18tk; 4,5mcg+160mcg 1annus 60annus 18tk; 4,5mcg+160mcg 1annus 60annus 2tk; 4,5mcg+160mcg 1annus 120annus 3tk; 4,5mcg+160mcg 1annus 60annus 3tk; 4,5mcg+160mcg 1annus 60annus 10tk; 4,5mcg+160mcg 1annus 120annus 2tk; 4,5mcg+160mcg 1annus 30annus 1tk; 4,5mcg+160mcg 1annus 120annus 1tk

Estland - Estnisch - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsioonipulber - 9mcg+320mcg 1annus 60annus 10tk; 9mcg+320mcg 1annus 60annus 18tk; 9mcg+320mcg 1annus 60annus 1tk

Estland - Estnisch - Ravimiamet

astrazeneca ab - esomeprasool - süste-/infusioonilahuse pulber - 40mg 1tk; 40mg 10tk

Estland - Estnisch - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsiooniaerosool, suspensioon - 4,5mcg+160mcg 1mõõtannus 120mõõtannus